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ABSTRACT
The arrival of next-generation sequencing (NGS)
technologies has led to novel opportunities for
expression profiling and genome analysis by
utilizing vast amounts of short read sequence
data. Here, we demonstrate that expression pro-
filing in organisms lacking any genome or
transcriptome sequence information is feasible by
combining Illumina’s mRNA-seq technology with a
novel bioinformatics pipeline that integrates
assembled and annotated Chinese hamster ovary
(CHO) sequences with information derived from
related organisms. We applied this pipeline to the
analysis of CHO cells which were chosen as a
model system owing to its relevance in the produc-
tion of therapeutic proteins. Specifically, we
analysed CHO cells undergoing butyrate treatment
which is known to affect cell cycle regulation and to
increase the specific productivity of recombinant
proteins. By this means, we identified sequences
for >13000 CHO genes which added sequence
information of 5000 novel genes to the CHO
model. More than 6000 transcript sequences are
predicted to be complete, as they covered >95%
of the corresponding mouse orthologs. Detailed
analysis of selected biological functions such as
DNA replication and cell cycle control, demonstra-
ted the potential of NGS expression profiling in
organisms without extended genome sequence to
improve both data quantity and quality.
INTRODUCTION
Development of next generation sequencing (NGS) plat-
forms such as Illumina’s Genome Analyzer (Solexa
Sequencing), Roche’s 454 method or the ABI Solid
Sequencers have provided novel tools for expression
proﬁling and for genome analysis (1). Each technology
has diﬀerent properties with respect to lab handling,
read length and quality, and sequence output. Also, the
chosen methodology has implications on subsequent data
analysis that may be a considerable challenge. Only
recently, current available NGS methods have been
described in detail in the reviews by Metzker (2) or
Shendure et al. (3). The Illumina Genome Analyzer
platform used in this study allows to sequence millions
of (relatively short) reads in parallel, resulting in the gen-
eration of substantial amounts of mRNA or DNA
sequence data in only one single experiment, and is espe-
cially well-suited to perform sensitive (very detailed)
transcriptome analyses. NGS methods have already been
shown to address a large variety of diﬀerent problems,
ranging from reliable expression proﬁling and splice
variant analysis in organisms where reference genomes
are known (4–7), the detection of sequence and structural
variations in the human genome (8) and the characteriza-
tion of new transcription factor binding motifs (9) to the
analysis of folding principles of the human DNA in the
nucleus (10).
Here we applied NGS for gene expression proﬁling in
Chinese hamster ovary (CHO) cells. Despite the fact that
CHO cells are widely used for the production of therapeu-
tic proteins (mainly monoclonal antibodies), there is
currently no comprehensive sequence information descri-
bing their genome or transcriptome. Recombinant
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agents in the last decade and their demand is rapidly
increasing. They are, for example, currently used in the
treatment of a variety of oncology and inﬂammatory
diseases (11) and are usually produced in mammalian
cell culture to achieve the extensive post-translational
modiﬁcations such as glycosylation that is required for
optimal function in terms of half-life, stability, antibody-
dependent cell-mediated cytotoxicity (ADCC) and
complement-dependent cytotoxicity (CDC). Given this
high demand, there is a need to improve process eﬃciency
in antibody production. Therefore, a better understanding
of the biology of the production cell lines is a key factor
(12,13). However, despite their importance, little is known
about the complex intracellular processes in CHO cells,
for example, changes in the transcriptional landscape.
Such large-scale datasets would enable both a detailed
analysis of a speciﬁc phenotype of a certain cell clone
(e.g. cell-speciﬁc productivity) and a comprehensive
molecular picture of the cellular responses to environmen-
tal changes such as a change in the composition of cell
culture media (14). Thus, these data could greatly help to
improve cell lines and production processes to ﬁnally
obtain high recombinant product concentrations of
correctly glycosylated antibodies.
The major drawback for the application of genomics
approaches in Chinese hamster cell lines so far is given
by the fact that the complete genome sequence is not avail-
able. This makes (powerful) large-scale expression
proﬁling with standard microarray platforms diﬃcult.
Recently, considerable progress has been achieved by
large-scale expressed sequence tag (EST) sequencing of
the CHO transcriptome, which has resulted in a custom-
made CHO-speciﬁc Aﬀymetrix microarray (15,16). This
array currently detects gene expression of 10000 CHO
genes. In general, this approach suﬀers from two limita-
tions. First, only a fraction of the expected number of the
expressed genes in CHO cells is likely to be present on the
chip, as they have not been detected by EST sequencing
yet. Second, chip probe design without the complete
genome sequence is diﬃcult, as reliable genome informa-
tion is mandatory to avoid cross-hybridization eﬀects
between two or more genes. For other important model
organisms such as the minipig or cynomolgus, no infor-
mation on the genome or transcriptome level is available,
making chip design impossible.
In this study, CHO mRNA sequencing using Illumina’s
GAII was carried out to demonstrate the feasibility of
performing reliable and detailed expression analysis of
organisms without an appropriate reference genome,
solely based on the information of the genomes and
transcriptomes of related species (mouse and rat).
Moreover, we established a computational workﬂow for
pre-processing of the CHO NGS data that greatly sup-
ported subsequent expression analysis steps.
In particular, we propose to perform a transcriptome
assembly of the NGS reads in the ﬁrst step, in order to
obtain longer CHO sequence contigs. Those contigs are
likely to represent the true CHO sequences, and therefore
capture mutations, insertions and deletions, which are
present in the Chinese hamster in comparison with
related species. In the second step, the contigs can be
reliably annotated to a reference genome (in our case the
mouse genome) to assign the respective orthologous genes
and to annotate potential functions. Read analysis is per-
formed as the third step by combining mapping informa-
tion from mouse, rat and CHO assembly sequences to
obtain ﬁnal read counts for CHO transcripts and genes.
As an exemplary study, we show that our workﬂow
allows high-throughput and large-scale expression proﬁ-
ling of CHO gene expression. To this end, we investigated
the eﬀect of sodium butyrate treatment, since it is relevant
for biotechnology applications and cell biology. Sodium
butyrate is an important supplement in mammalian cell
culture to increase the speciﬁc productivity of recom-
binant proteins in CHO cells (17). It has also been
analysed in the context of oncology as an inhibitor of
cell cycle progression and as an inducer of apoptosis in
cancer cell lines (18,19).
Sodium butyrate inhibits histone deacetylases leading
to a subsequent increase in the accessibility of the DNA
to transcription factors. Several studies have already
analysed the eﬀects of sodium butyrate treatment on dif-
ferent cell lines (17–21) and found that, among other
eﬀects, sodium butyrate mediates a down-regulation of
cell cycle proteins followed by an arrest of the cells in
the G1 or G2 phase (22).
Our analysis revealed two major advantages of applying
NGS for CHO expression proﬁling. First, biologically
meaningful expression analysis of CHO cells is possible
using NGS data. Many of the cellular processes and
genes leading to sodium butyrate-mediated cell cycle
arrest could be identiﬁed in a much greater detail
compared with a chip platform. Genome-wide expression
proﬁling by NGS can be performed without the time and
cost-intensive steps to compile a set of EST sequences, and
the error-prone design of custom-made expression arrays
in the absence of the complete genome sequence informa-
tion. Second, NGS can provide a signiﬁcant amount of
novel sequence information on CHO transcripts, which
can be used for further NGS studies or to gain a deeper
understanding of the CHO genome and transcriptome.
Sequencing data from 12 samples allowed for the
assembly of more than 6000 CHO transcripts that were
likely to be complete with respect to their orthologs in
mouse. Moreover, gene expression of more than 13000
genes could be proﬁled.
Finally, this study demonstrates the potential of a novel
bioinformatics pipeline combined with NGS data for the
analysis of other model organisms where no reference
genomes are available, but for which large-scale expres-
sion proﬁling would reveal an abundance of novel infor-
mation. These data will be required to globally elucidate
complex molecular networks in those genomically
‘unknown’ organisms.
MATERIALS AND METHODS
Cell culture, butyrate treatment and analytical methods
A recombinant IgG producing CHO cell line was
cultivated in a controlled fed batch process. The bioreactor
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inoculated with a viable cell concentration of 3.010
5
cells/ml. The pH was controlled at 7.1 and the dissolved
oxygen concentration at 60% air saturation by adjustment
of stirrer speed and aeration. Proprietary, chemically
deﬁned, serum-free basal and fed batch media were
used. Three cultivations using the same inoculum
pre-culture were performed in parallel. No butyrate was
added to the control culture, in the other two cultivations
butyrate was added at concentrations of 0.5mM, respec-
tively, 1.0mM, at cultivation Day 5.25.
Cell concentration and cell viability were determined
by the trypan blue exclusion method with a CEDEX
cell analyzer (Innovatis AG, Bielefeld, Germany).
Recombinant IgG antibody concentration was quantiﬁed
by surface plasmone resonance detection with a Biacore C
instrument (GE Healthcare Europe GmbH, Munich,
Germany). Samples for gene expression analysis were
taken at cultivation Days 0, 4, 6 and 8.
RNA isolation
RNA isolation was carried out using a MagMAX
Express-96 Magnetic Particle Processor (Ambion,
Austin, TX, USA) and the MagMAX-96 Total RNA
Isolation Kit (Ambion, Austin, TX, USA) according to
the manufacturer’s protocol. Total RNA concentration
was quantiﬁed by Nanodrop (NanoDrop Technologies,
Wilmington, DE, USA). RNA quality was characterized
by the quotient of the 28S to 18S ribosomal RNA
electropherogram peak using an Agilent 2100 bioanalyzer
and the RNA Nano Chip (Agilent Technologies, Santa
Clara, CA, USA).
Library preparation and sequencing
All libraries were prepared using the mRNA-Seq 8 sample
prep Kit (Illumina, San Diego, CA USA) according to the
manufacture’s instruction. In brief, ﬁrst, magnetic beads
containing poly-T molecules were used to purify mRNA
from 5mg of total RNA. Second, samples were chemically
fragmented and reverse transcribed into cDNA. Finally,
end repair and A-base tailing was performed before
Illumina adapters were ligated to the cDNA fragments.
After a gel size fractionation step to extract fragments of
200bp, 30ml of the puriﬁed samples were ampliﬁed by
15-cycle PCR. Ampliﬁed material was validated and
quantiﬁed using an Agilent 2100 bioanalyzer and the
DNA 1000 Nano Chip Kit (Agilent, Technologies, Santa
Clara, CA, USA).
Libraries were loaded onto the channels of the ﬂow cell
at 5–7pM concentration. Sequencing was carried out on
the Genome Analyzer II (Illumina, San Diego, CA, USA)
by running 36 cycles using Illumina’s Single Read Cluster
Generation Kit and 36 Cycle Sequencing Kit according to
the manufacturer’s instructions.
Read mapping
Short read sequences were mapped to mouse and rat tran-
scripts obtained from Ensembl release 55 (23) [processed
by the ProSAS pipeline (24)] using the Bowtie mapping
algorithm (25). A maximum of four mapping errors were
allowed to account for the larger number of mutations to
be expected between CHO reads and the two reference
transcriptomes.
Mapping to assembled CHO contigs was also per-
formed with stricter mapping criteria of at most two
mismatches between CHO contig and a read. It is impor-
tant to note that Bowtie does not allow for insertions and
deletions to occur in the alignment between reference
sequences and read such that all matches are gapless.
CHO transcriptome assembly
Assembly strategies. To obtain longer CHO mRNA
sequences, which are useful in subsequent analysis steps,
two diﬀerent assembly strategies were applied and
combined in a ﬁnal CHO assembly. First, we computed
two de novo assemblies of all reads pooled for each of the
two ﬂow cells using Velvet (26). This led to an assembly of
the read data which is not limited to and biased towards
sequences known in a reference genome like in mouse or
rat, and may also contain contigs which are unique for
CHO, like poorly conserved transcript UTRs or novel
genes.
The second assembly strategy, which will be called
knowledge-based assembly, makes use of all known
Ensembl mouse transcripts (or the corresponding rat
orthologs) and all reads which have been mapped to
those sequences. Knowledge-based assembly is performed
by collecting all reads mapping to a speciﬁc mouse gene in
any of the 12 lanes and running Velvet on those short
reads. Annotation of reads is performed with respect to
the mouse and rat transcriptomes, as well as annotated
de novo contigs of CHO.
Contig annotation and selection pipeline. While
knowledge-based contigs are by deﬁnition already
assigned to their respective mouse transcripts, we used
BLAST (27) with parameters optimized for more dissim-
ilar sequence searches (word size of 16, a match score of 2,
a mismatch score of 3, as well as gap open and gap
extend penalties of 5 and 2, respectively, as suggested
by the NCBI) to identify similar Ensembl mouse tran-
scripts for CHO de novo contigs that are longer than
50bp (all other contigs are ignored).
The hits returned by BLAST were ﬁltered for matches
with signiﬁcant E-values of smaller than 10E
7 and hits
where BLAST high scoring segment pairs (HSPs) cover at
least 60% of a contig. This criterion led in most cases to a
single mouse gene, which was assigned to the CHO contig.
In the case of more than one mouse sequence matching the
contig with the speciﬁed criteria, we selected the best tran-
script with respect to contig coverage and sequence
identity. Unspeciﬁc contigs, i.e. those matching more
than ﬁve transcripts with a similar quality, were ﬁltered
out.
Contigs which could not be assigned to any mouse tran-
script at all may represent misguided assemblies, novel
transcripts, splice variants or non-conserved regions (e.g.
UTRs) of known transcripts. They were not used for gene
expression proﬁling.
Nucleic Acids Research, 2010,Vol.38, No. 12 4001Final CHO assembly. Finally, all contigs assigned to a
gene in any of the three assemblies, de novo and
knowledge-based, were combined and ﬁltered for redun-
dant information by detecting overlaps between the
contigs. Overlapping sequences were merged, and single-
ton contigs with no overlap with others were also retained
in the ﬁnal set of contigs for a gene.
Read mapping pipeline
Reads were mapped to three diﬀerent sequence sets
(mouse, rat and CHO contigs) in parallel. Then we
combined the information of the mapped reads in the
second step. As discussed above, we used the mouse
genome as a reference dataset. Therefore, reads mapping
to mouse transcripts or CHO transcriptome contigs were
summarized for the respective mouse genes. Reads
mapping to rat transcripts were projected to mouse
genes via the mapping of orthologous genes between
mouse and rat provided by Ensembl. Reads mapping to
multiple genes, either within a single reference dataset or
between diﬀerent references were handled as suggested by
Mortazavi et al. (5). They were assigned to the respective
genes proportional to the expression level of the respective
genes as measured by unique reads.
Expression proﬁling and biological interpretation
of the results
For the analysis of diﬀerential expression of genes between
butyrate-treated cells and control cells using NGS data,
reads obtained for each gene in a lane were counted and
RPKM values were computed as proposed by Mortazavi
et al. (5). Fold changes were computed as the ratio of the
RPKM values obtained for a gene. The signiﬁcance of
diﬀerential gene expression was computed using the
SAGEBetaBin method (28), and only genes with an
absolute fold change >1.4 and a SAGEBetaBin signiﬁ-
cance score <0.01 were used for further analyses steps.
For Aﬀymetrix arrays, which contain more than
23000 probes detecting 10425 Ensembl mouse genes,
CEL ﬁles were processed using R and Bioconductor
(29). Normalization was done using the MAS5 normaliza-
tion (which normalizes all chips to the same mean value),
and fold changes were computed as the ratio of the
normalized and log2-transformed signal intensities. The
LIMMA package (30) was used to compute adjusted
P-values for all comparisons. In analogy to NGS data,
all probes assigned to known Ensembl genes with an
absolute fold change >1.4 and a P-value <0.01 were
used in further analyses steps.
Results were interpreted in the context of biological
processes and functions, as well as networks and path-
ways through the use of Ingenuity Pathways Analysis
(Ingenuity Systems Inc., Redwood City, CA, USA). For
the analysis of gene set enrichment in functional categories
Fisher’s exact test was used.
RESULTS
Throughout the analysis, we made extensive use of the
mouse genome as a reference dataset for CHO sequences,
i.e. to provide gene names for CHO genes and, more
important, functional annotations of speciﬁc genes. This
approach has also been proposed by Wlaschin et al. (31)
and was used for the annotation of the existing CHO
microarray. All CHO sequences will be analysed with
respect to the corresponding mouse genes and are
assigned to their speciﬁc mouse orthologs as described
below. It has to been noted that the CHO EST sequences
have not been used throughout this study as the data are
not publicly available. But in principle, our pipeline also
supports the use of such data in read mapping andanalysis,
if available. The analysis workﬂow is summarized in
Figure 1 and a free Java implementation of the complete
pipeline is available at http://unoseq.sourceforge.net.
Mouse,
Ensembl
Rat,
Ensembl
CHO
Assembly
Bowtie Reads
Combine mapping
information from
 different sources
using orthologous
 gene information 
Mapped
Reads
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gene 
expression 
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Figure 1. The bioinformatics workﬂow used for CHO data processing. In the ﬁrst step, reads are assembled by two diﬀerent strategies: (i) a de novo
approach using Velvet starting with all reads and (ii) a knowledge-based approach using all reads mapping to a mouse gene (or the corresponding rat
ortholog) again by applying Velvet. After computation and annotation of the ﬁnal CHO transcriptome assembly, the reads that mapped against all
three reference sequence datasets were used for gene expression proﬁling.
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In total, we sequenced 12 lanes of CHO mRNA
originating from three diﬀerent cell cultures (control
without butyrate, 0.5mM butyrate as well as 1.0mM
butyrate) and three time points (Days 0, 6 and 8). In the
control cell line, we sequenced two lanes for Day 0, three
lanes for Day 6 and one lane for Day 8. From the 0.5mM
butyrate culture, one lane from each of the three time
points were sequenced, while for 1.0mM butyrate-treated
culture two lanes for Day 6 and one lane for Day 8 were
analysed. Each sample was sequenced on a single lane of a
ﬂow cell. Sequencing resulted in 11–15 mio. 36bp reads
per lane (Table 1) passing Illumina’s quality ﬁlter with a
total of 173 Mio. reads and 5.9 GB of CHO transcript
sequence data. The results from Day 6, 18h after
butyrate addition, are the most interesting from a
biopharmaceutical point of view, as the cellular eﬀects
leading to a higher cell-speciﬁc productivity of butyrate-
treated cultures are likely to be detectable while cell via-
bility is not yet signiﬁcantly reduced by butyrate treat-
ment. We, therefore, sequenced the control samples and
1.0mM butyrate samples of Day 6 in technical replicates
of three and two, respectively, in order to allow for a
reliable estimation of the variance in read counts
introduced by technical eﬀects. Sequencing of diﬀerent
time points was performed to gather transcript data also
on genes which are expressed only at speciﬁc days of the
cultivation process. Reads were then used for
transcriptome assembly and gene expression analysis.
The bioinformatics workﬂow is summarized in Figure 1,
and the results of the single steps of the workﬂow
(assembly and mapping) will be described in the following.
Short read data has been deposited in NCBI’s Short Read
Archive under project id SRA010967.
CHO transcriptome assembly: extending the CHO
sequence space
Reads across the entire length of the transcripts present
in the samples were obtained. In transcripts which are
covered multiple times by read data, reads are likely to
overlap and, therefore, can be assembled into longer
contigs using short read assembly algorithms.
We assembled the reads obtained from the 12 lanes
using two diﬀerent assembly strategies as described in
the ‘Materials and Methods’ section. This resulted in
two de novo assemblies (one for each ﬂow cell) and one
knowledge-based assembly. The ﬁnal CHO transcriptome
assembly was then computed by merging all contigs
assigned to a gene and resolving overlaps between the
contigs.
The results of the two de novo assemblies are
summarized in Table 2. We used BLAST (27) to assign
contigs to the Ensembl mouse transcriptome. Two criteria
were used to ﬁlter matches. We applied a strict E-value
threshold of 10E
7 and demanded for at least 60% of the
contig sequence to overlap with the mouse transcript. By
this means, 53% (52803) of the de novo contigs in Flow
cell 1 and 44% (55267) of the contigs in Flow cell 2 could
be assigned to mouse orthologs. Out of those, >90%
could be assigned to an unique gene in mouse and were,
therefore, retained in the dataset. About 50% of the
Table 1. Read mapping statistics for all 12 lanes sequenced on two ﬂow cells
Lane Reads Mouse Rat CHO All mapped
All Exclusive All Exclusive All Exclusive
1 12201860 3569738 420713 3064690 235757 4168909 1597293 7369538
2 14627832 4390238 453707 3778402 281312 4996910 1840362 8866445
3 14382040 4306491 437651 3695549 272113 4936324 1814889 8692089
4 14853725 4375171 462080 3794065 285486 5128705 1930695 9004221
5 12824961 3462861 391391 2998615 233884 4117863 1578307 7363436
6 12622323 3473606 394837 2960651 242255 4226336 1735168 7140443
7 14063619 3497681 436575 3010972 267506 4369923 1856925 7508741
8 11349612 2919955 346243 2495134 216963 3685415 1553036 6163541
9 15799183 3965147 511692 3413354 298204 4984857 2147939 8666756
10 14629652 3411264 478117 2938477 265613 4315480 1891912 7564842
11 13611066 3743496 438070 3229333 279112 4571083 1903044 7801213
12 12166856 3061743 388744 2636835 236914 3813744 1627339 6557042
Lanes 1–5 are contributed by Flow cell 1, lanes 6–12 by Flow cell 2. Column 2 displays the total number of reads passing the quality ﬁltering. The
‘All’ column shows the total number of reads mapping to a reference sequence dataset and the ‘Exclusive’ column shows the number of reads
mapping only in the respective sequence set and not in the two others. Finally, the ‘All Mapped’ column shows the number of reads that can be
recovered by the proposed mapping strategy.
Table 2. Statistics on the contigs obtained by the two de novo
assemblies
Description Flow
cell 1
Flow
cell 2
Number of contigs (contig length >50nt) 98660 124339
Average contig length 230 227
No signiﬁcant BLAST hits in mouse 45857 69072
No signiﬁcant BLAST hits in mouse
(contig length >100nt)
22104 34110
Number of signiﬁcant BLAST hits in mouse
(E-value<10E
7)
52803 55267
Matching unique mouse genes 48265 50416
Distinct Ensembl genes mapped by contigs 9363 9762
Contigs were searched against the mouse Ensembl transcriptome with
BLAST (as described in the ‘Materials and Methods’ section) and a
strict E-value threshold of smaller than 10E
7 was used.
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transcriptome were smaller than 100nt. Extending the ref-
erence sequence dataset to the complete RefSeq database
allowed the assignment of 7954 additional contigs (14% of
the contigs with no hits in the mouse Ensembl
transcriptome) to unique RefSeq sequences which suﬃce
the criteria deﬁned above. These contigs were assigned to
sequences from rat (2812 contigs), mouse RefSeq only
sequences (1345 contigs), Schistosoma mansoni (930
contigs), human (919 contigs), Macaca mulatta (465
contigs), chimpanzee (419 contigs) and some other
organisms.
In contrast to the de novo assembly strategy, for the
knowledge-based assembly all reads mapping to a
speciﬁc Ensembl mouse gene (or its corresponding rat
ortholog) in any of the 12 lanes were collected and then
assembled. This resulted in 93016 contigs with an average
length of 272nt. As expected, these contigs were longer on
average than contigs obtained from the de novo assembly;
they represented sequences for 13013 diﬀerent mouse
Ensembl genes.
Our ﬁnal assembly was computed as a combination
of de novo and knowledge-based assemblies of the CHO
transcriptome and consisted of 92272 contigs. These were
assigned to 13375 mouse Ensembl genes. The average
length of the contigs could be increased to 352bp by
combining overlapping contigs. Almost 8000 contigs
were >1000nt in length with the largest ones having a
length of >12000nt. They represent mRNAs of the
Protocadherin Fat 1 gene and the Serine/threonine-protein
kinase SMG1.
Contigs were then aligned to the Ensembl mouse
transcriptome using standard sequence alignment in
order to estimate the completeness of the CHO contigs
with respect to mouse transcripts. As shown in Figure 2,
>6000 reference transcripts are almost completely covered
by CHO sequence (coverage >95%), and therefore are
likely to be also nearly complete for CHO. The average
transcript coverage is 66.9%.
While the CHO Aﬀymetrix microarray measures
expression levels for 10425 genes, at least 13375 genes
are detectable by NGS as they lead to assembled
contigs. Additionally, lower abundance genes with
orthologs in mouse and rat can be detected by reads
mapping directly to mouse or rat transcripts. A compari-
son of the genes present on the chip and the genes present
in the CHO assembly (Figure 3) shows that 8404 genes
are detectable on both platforms, while 4971 genes are
obviously expressed in the CHO cell line being analysed,
but escaping detection on the chip.
By using this thorough pre-processing and assembly
strategy for the read data, we could generate a signiﬁcant
amount of sequence information for CHO without any
prior information on the CHO transcriptome.
Additionally, as highly expressed genes lead to many
reads which in turn can likely be assembled to contigs,
we are able to proﬁle exactly those genes that are really
present in a speciﬁc cell line or under a speciﬁc treatment.
As shown above, longer contig sequences can be reliably
assigned to orthologous genes in mouse (or other organ-
isms) using BLAST, even in cases where less conserved
parts including mutations, insertions and deletions exist.
Since they represent the true CHO sequence of a transcript
(including many of the CHO-speciﬁc insertions, deletions
and mutations), reads originating from CHO are likely to
ﬁt better to CHO contigs than to transcriptomes of related
organisms like mouse and rat. This is especially important,
as short read mapping algorithms allow only for a limited
number of mutations (to guarantee speciﬁcity of the
mapping) and in most cases require non-gapped matches
of the reads to the reference sequence. Reads originating
from regions with a larger variability in CHO compared
with mouse and rat can, therefore, only be detected
knowing the true CHO sequence. In the following
Figure 2. Coverage of mouse Ensembl transcripts by CHO contig sequences. More than 6000 transcripts can be expected to be nearly complete with
a coverage of >95% with respect to mouse. The average mouse transcript coverage is 66.9%.
4004 Nucleic Acids Research, 2010,Vol.38, No. 12section, the CHO assembly proves to be very useful and
allows the recovery of many reads that do not map to the
transcriptomes of related organisms.
Making the most out of read data: read mapping pipeline
All reads have been mapped to three diﬀerent reference
datasets, namely mouse and rat (those mappings have
already been used to compute the knowledge-based
assembly) and to the ﬁnal CHO transcriptome assembly
in order to recover as many reads as possible and identify
their genomic origin. We noted that adding the human
transcriptome as a fourth dataset did not improve the
mapping statistics, and therefore has not been used for
further steps (data not shown). Based on the read
mapping against the CHO transcriptome assembly, we
estimated the sequencing error rate to be 0.8% per
base indicating a very high sequence quality of the short
reads used in our experiment. More than 90% of the read
map either perfectly to the reference sequence set or have
at most one mismatch. For more details see
Supplementary Table S1.
About 60% of all reads obtained in a lane could be
assigned to at least one sequence in one of the reference
datasets and were recovered for gene expression proﬁling
(Table 1). The majority of mapped reads (70%) map to
more than one reference sequence dataset at the same
time. In more than 90% of those cases, a single mouse
gene (or in the case of a mapping to the rat transcriptome,
the orthologous rat gene) was identiﬁed showing that the
mapping of reads across the diﬀerent species is highly
consistent.
Finally, the statistics showed that mapping reads to a
single reference sequence dataset is less powerful than the
combination of all three datasets. This proposed mapping
strategy can greatly help to recover the origin of as many
reads as possible. As indicated, 30% of reads map
exclusively to one reference dataset. The CHO assembly
dataset contributes the majority of those reads, 70% of
the exclusive reads are mapped to CHO sequences
showing the importance of performing a thorough
pre-processing of the data for read mapping. About
55% of all mapped reads and 35% of all reads in each
lane would have been recovered if only the assembled
contigs were used. Since those contigs also contain infor-
mation on reference transcripts in terms of the
knowledge-based assembly, this number represents an
upper limit of the reads which would be recovered
without any information on genomes from related
organisms.
Overall, the identity of a signiﬁcant amount of reads
could be determined. Those were used subsequently to
perform a reliable, in-depth expression proﬁling of CHO
cells undergoing sodium butyrate treatment.
Eﬀects of butyrate treatment on cultivated CHO cells
In order to gain a deeper understanding of the eﬀects
of butyrate treatment in CHO cells, we analysed
diﬀerentially expressed genes detected by mRNA
sequencing in a controlled CHO cultivation process.
The eﬀects of butyrate on the CHO cell culture are
summarized in Figure 4. Prior to butyrate addition at cul-
tivation Day 5.25, the viable cell number, the cell viability
and the recombinant product concentrations were compa-
rable across the three cultures, a fact which can be
attributed to the controlled process conditions. Addition
of butyrate to the CHO fed batch process resulted in a
butyrate concentration-dependent decrease of the viable
cell number from Day 6 onwards, a decline of cell viability
was apparent from Day 7. Whereas the 1.0mM butyrate
treatment led to a decrease of the ﬁnal product concentra-
tion at Day 10 compared with the control culture (grown
under the same conditions but without butyrate addition
on Day 5.25); a butyrate concentration of 0.5mM in the
cultivation medium slightly increased the ﬁnal product
concentration by 5%. Since the viable cell number
decreased at the same time, this translates into an
increase of the cell-speciﬁc productivity of about 14% at
Day 10 (compared with control).
In addition to NGS, expression proﬁling was also
carried out using the custom Aﬀymetrix CHO array in
order to compare these two platforms. Ingenuity
Pathway Analysis was used to analyse diﬀerentially
expressed genes and to enrich aﬀected processes with addi-
tional information from the literature.
As discussed above, we focused on the comparison
between the control group (no butyrate treatment) and
the cells treated with butyrate at 1.0mM at Day 6 of the
experiment (18h after butyrate addition). Technical
replicates (three lanes for the control group and two
lanes for butyrate-treated cells) sequenced for those two
samples were used as a reliable estimation of the diﬀer-
ences between the cell lines due to random sampling eﬀects
and were included in the computation of the statistical
signiﬁcance of diﬀerences detected between the two
samples.
In this comparison, 1785 genes were identiﬁed as being
deregulated by an absolute fold change of at least 1.4 (and
a signiﬁcance value <0.01) in the NGS data. One
thousand and thirty-seven genes were up-regulated in the
control group while 748 genes were down-regulated under
butyrate treatment. In comparison, using Aﬀymetrix
microarrays 595 genes were identiﬁed as being
Ensembl Genes available on different platforms 
Affymetrix Chip
CHO NGS Assembly  8404 2024 4971 
Figure 3. Overlap of Ensembl genes detectable on the custom
Aﬀymetrix CHO microarray and detectable using the CHO assembly.
Please note that not all genes detectable by NGS during expression
proﬁling are contained in the assembly, e.g. because they are expressed
at too low levels. In those cases orthologous to mouse or rat can be
detected by the mapping strategy and allow for proﬁling the expression
of the corresponding CHO genes.
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overlap between genes identiﬁed by NGS and by the
CHO chip was large with 57% for the down-regulated
genes (103 genes) and 55% of the up-regulated genes
(231 genes). A signiﬁcant amount of 752 deregulated
genes could only be detected by NGS as they are not
measured by a probe on the Aﬀymetrix chip. Similar
overlaps between genes detected by NGS and Aﬀymetrix
have also been described by Tang et al. (32).
The identiﬁed genes were involved in several biological
functions, and many functional categories were signiﬁ-
cantly aﬀected according to an over-representation
analysis using Fisher’s exact test. Processes identiﬁed by
NGS along with the Aﬀymetrix array included the regu-
lation of the cell cycle, cellular growth and proliferation,
DNA replication, recombination and repair, cellular
assembly and organization, cellular movement, several
metabolic pathways (like purine and pyrimidine metabo-
lism) as well as other processes. Overall, those results
were consistent with other published data on genes and
functional categories regulated under butyrate treatment
(20–22,33).
As shown in Figure 5a, NGS detected more signiﬁcantly
deregulated genes in those cellular processes known to be
inﬂuenced by sodium butyrate than the Aﬀymetrix chip.
For example, with NGS we identiﬁed 197 genes involved
in the regulation of the cell cycle in contrast to 115 genes
detected on the chip. The majority of those additionally
identiﬁed genes (53 in the speciﬁc example and 65% on
average across all categories) originated from genes, which
are not represented by a probe on the Aﬀymetrix chip. For
genes which were detected as signiﬁcantly deregulated on
both platforms, the correlation of their fold changes was
high (Pearson correlation coeﬃcient: 0.87, see also
Supplementary Figure S1) indicating a good consistency
of the expression measurements between NGS and
Aﬀymetrix chips which has also been described by
Marioni et al. (34). As shown in Supplementary Figures
S2 and S3 genes, which are measured as signiﬁcantly
deregulated in a platform usually showed the same direc-
tion of regulation (though not necessarily statistically sig-
niﬁcant) in the other platform. This indicates that many of
the additional genes only detected by NGS as being sig-
niﬁcant, although they are measured on the chip, are due
to the stringent threshold criteria applied to ﬁlter for
signiﬁcantly deregulated genes. Some of them may also
have been identiﬁed because of the higher accuracy of
NGS in measuring absolute expression levels as described
by Fu et al. (35) and Marioni et al. (34).
Overall, while both technologies identify the same
cellular processes as being regulated, NGS can provide a
more detailed picture mainly due to the fact that the tech-
nology allows for an unbiased look into the transcriptome
which is not restricted to those genes spotted on the
Aﬀymetrix chip.
In the following, we will analyse selected pathways and
associated genes identiﬁed from the NGS data. A list with
log ratios and P-values for all genes can be found in the
Supplementary Data.
Regulation of cell-cycle genes. As shown in Figure 5a,
197 genes associated with the cell cycle (P-value: up to
6.8E
16) were diﬀerentially regulated between the control
group and butyrate-treated cells. Below, we will describe
two examples that—like many of theses genes—are
involved in checkpoint control pathways (Figure 5b and c).
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Figure 4. Cultivation data of recombinant CHO fed batch process. Normalized viable cell concentration (VCC; normalization to maximal VCC of
control process without butyrate addition), cell viability and recombinant IgG product concentration are shown. Butyrate was added to the culture at
d=5.25 as indicated by the arrow. Sampling times for RNA extraction were d=0, 4, 6 and 8.
4006 Nucleic Acids Research, 2010,Vol.38, No. 12Figure 5. Changes in gene expression mediated by 1.0mM butyrate compared to the control group on Day 6 of the experiment. Results from gene
expression analysis of cells treated with 1.0mM butyrate compared to the control on Day 6 of the experiment (18h after butyrate addition). In the
networks shown, genes marked in redare down-regulated in butyrate-treated cellswhereas genesshown in greenare up-regulated. Pathwaysand networks
are taken from Ingenuity Pathway Analysis. (a) Top three functional categories and number of regulated genes detected by NGS and by Aﬀymetrix,
indicating that NGS provides a more detailed look into transcriptional changes mediated by butyrate. (b) and (c) Regulation of cell cycle genes through
butyrate. (b) Up-regulation of BTG2 is known to lead to a down-regulation of the Cyclin E/CDK2 complex as well as Cyclin D1 (blue arrows).
(c) Pathway of genes involved in mitotic check point control. (d) and (e) Example for the high consistency of diﬀerential gene expression detected by
CHO NGS shown by the down-regulation of MCM genes at Day 6 in cells treated with 1.0mM butyrate. The MCM complex and associated genes play a
role in the initiation and the elongation phases of eukaryotic DNA replication, speciﬁcally the formation and the elongation of the replication fork.
(d) shows down-regulated genes as detected by the NGS approach while part (e) shows deregulated genes detected by the Aﬀymetrix CHO chip. Several
genes (MCM2, MCM4, MCM8 and CDT1) are not measured on the chip but ﬁt well into the complete down-regulation of the complex.
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was found to be up-regulated in butyrate-treated cells
and may play an important role in butyrate-mediated
cell cycle arrest. BTG2 is activated by a number of diﬀer-
ent stimuli, including DNA damage or cellular stress and
has been described to lead to a down-regulation of the
Cyclin E/CDK2 complex as well as Cyclin D1 (36) that
are essential in the progression of the cell cycle from G1
to the S phase, which is in agreement with our results.
Among the proteins belonging to the cyclin family,
which are responsible to regulate cyclin-dependent
kinases, many members are diﬀerentially regulated after
butyrate addition compared with the control. Examples
for down-regulated cyclins are CCNA2, which promotes
G1/S or G2/M transition through activation of CDC2 or
CDK2, cyclin B1 and B2, cyclin D1, as well as cyclins E1,
E2 and F. Cyclin G2, which is known to increase cell cycle
arrest is up-regulated as are cyclin H and I. CDK2 and
CDK6 are also down-regulated under butyrate treatment,
as well as many members of the CDC group of proteins
like CDC2, which is part of the M phase promoting factor
(MPF) complex, and others.
The almost 4-fold up-regulation of TP53INP1 (tumor
protein p53 inducible nuclear protein 1) and SMAD3 are
additional indications of the G1 phase arrest of
butyrate-treated cells. TP53INP1, which has been shown
to lead to cell cycle arrest in G1 (37), is functionally
associated with p73 to regulate cell cycle progression and
apoptosis, independently from TRP53 (which is down-
regulated under butyrate treatment). SMAD3 is the key
mediator of TGF-b signaling and has also been shown to
increase cell cycle arrest (38).
In addition to the cell cycle control genes, 22 genes
(P-value: 2.2E
8) were involved in cytokinesis. Twenty
were down-regulated in butyrate-treated cells including
the concerted down-regulation of Aurora kinases A
and B (which associate with microtubules during chromo-
some movement and segregation), as well as several
members of the KIF family (kinesin superfamily of
microtubule-associated motors) proteins which facili-
tate the movement of chromosomes during cell division.
Regulation of DNA replication, recombination and repair
genes. Many genes regulated by butyrate were involved
in DNA replication, recombination and repair. DNA rep-
lication was signiﬁcantly aﬀected (P-value: 6.9E
11) and
contained 46 genes, 45 of which were down-regulated. The
most prominent complex in this network, which is shown
in Figure 5d and e, corresponded to a highly connected
component containing the mini-chromosome maintenance
complex (MCM) and associated genes like CDC6 and
CDC7, members of the origin recognition complex
(ORC1L and ORC6L), CDT1 and RPA2 and RPA3.I n
comparison, the CHO chip identiﬁed merely nine out of
the 15 genes in this complex as being down-regulated, but
could not detect the regulation of the six other genes as
they are not represented by a probe on the chip. The only
gene which was up-regulated in this network was RAD17.
RAD17 is known to be involved in DNA damage recog-
nition and, after being phosphorylated by ATR, it can
induce the arrest of cells in the G2 phase.
Furthermore, 22 genes involved in the segregation
of sister chromatids and chromosomes (P-value: 5.5E
8),
11 genes involved in the orientation and alignment of chro-
mosomes (P-value: 2.5E
7), as well as 14 genes involved in
the formation of the mitotic spindle (P-value: 6.8E
6) like
NDE1, which is important for microtubule organization,
were down-regulated under butyrate treatment.
All the above-mentioned genes are essential compo-
nents of the eukaryotic DNA replication apparatus, and
their concerted down-regulation after butyrate addition
indicates that DNA replication prior to mitosis as well
as important steps during mitosis are inhibited by
butyrate.
Changes in the extracellular space. Several other
diﬀerentially expressed genes aﬀect the composition of
the extracellular matrix or represent growth factors
and chemokines. Several members of the matrix-
metalloprotease family which are involved in the break-
down of extracellular matrix in normal physiological pro-
cesses, such as embryonic development, reproduction and
tissue remodeling were found to be down-regulated in the
treated samples (MMP3, MMP9, MMP14, MMP19 and
MMP23B). In correspondence with this ﬁnding were
changes in the expression of collagens, where Col1A1
was found to be >5-fold up-regulated in contrast to
Col4A5, Col5A2, Col6A1 and Col8A1, which were all
down-regulated.
Besides changes in the extracellular matrix, we found
several growth factors like CTGF and NGF to be up- or
in the case of FGF13 to be down-regulated.
TGF-  signaling pathway and other regulated
processes. We also observed a down-regulation of the
cytokine TGF-b and a reduction of its signalling by the
down-regulation of well-characterized downstream targets
like SEPRINE-1, TGIF, JUN and JUNB after butyrate
treatment. Furthermore, TGF-b may be involved in
remodeling of the extracellular space (as discussed
above) by the regulation of metalloproteases and
collagens, which is in line with the above-mentioned
ﬁndings for butyrate-treated CHO cells, and therefore
strongly indicate a role of butyrate treatment onto the
TGF-b signaling pathway.
In addition to the processes and pathways discussed
above, several metabolic pathways were inﬂuenced by
butyrate. These included genes involved in pyrimidine
and purine, as well as lipid metabolism. Again we found
that NGS data can identify many more genes associated
with those processes than the chip platform as shown in
the supplementary Figure S4.
DISCUSSION
In recent years, expression proﬁling has mainly focussed
on organisms with well-characterized genomes for which
well-established chip platforms were available. However,
from expression proﬁling of organisms, where only frag-
mented or no information on the corresponding genome
or transcriptome is known (hence no chip platforms are
4008 Nucleic Acids Research, 2010,Vol.38, No. 12currently available) and that play an important role with
respect to biotechnological and pharmaceutical applica-
tions, relevant new insights can be expected.
In this study, we applied NGS to the problem of expres-
sion proﬁling without a reference genome using the
example of CHO cells undergoing butyrate treatment.
CHO cells lines are highly relevant for the production of
biopharmaceuticals such as therapeutic antibodies.
We demonstrated that, by using a thorough pre-
processing of the read data combined with an advanced
mapping strategy, expression proﬁling in CHO cells is
possible using NGS at a yet unknown resolution. By
applying two diﬀerent assembly strategies, i.e. de novo
assembly of the reads without prior knowledge and a
knowledge-based strategy, which utilizes reference
sequences from mouse and rat, we could generate a sig-
niﬁcant amount of sequence information on the Chinese
hamster transcriptome. Our assembly strategy could con-
tribute partial transcript sequences for >13000 CHO
genes. More than 6000 of those transcript sequences are
likely to be complete as they cover >95% of the
orthologous mouse transcript mRNAs. On average, refer-
ence transcripts in mouse are covered by 66.9% with CHO
sequences indicating that for expressed genes in the
samples a large transcript coverage and a huge amount
of sequence information could be generated. This
sequence information has the potential to improve expres-
sion proﬁling for the CHO model in the future. Moreover,
this information comes at no additional time and cost
as expression proﬁling and sequencing of the CHO
transcriptome are performed in a single experiment, a
clear advantage over the expensive generation of EST
libraries.
While making extensive use of the mouse genome to
annotate CHO genes via BLAST, we noted that some
caution is required with respect to the assignment of
CHO gene functions. Due to variable degrees of
sequence homology, not all of the transcripts proﬁled
may indeed perform comparable functions in both organ-
isms. Hence, our approach of deﬁning gene identity will
certainly not replace a thorough annotation of a given
transcriptome. It must be kept in mind, however, that
this is a general problem of all (genome) sequencing and
annotation projects and that data quantity and data
quality across diﬀerent genomes do not necessarily
compare. Moreover, a growing conundrum is generated
by the gap between data generation and annotation.
In order to recover the genomic origin of as many
mRNA reads as possible, we applied a mapping strategy
which makes use of closely related species (mouse and rat),
as well as annotated contigs from the CHO transcriptome
assembly. In total, about 60% of the reads sequenced
could be assigned to genes and were used for gene expres-
sion proﬁling. In comparison, when mapping e.g. mouse
transcriptome reads on the relatively well-annotated
mouse genome, one can usually map 80% of the reads
to exons and UTRs of known transcripts. The other
20% are likely to correspond to yet unknown transcripts
or splice variants, novel exons or UTRs and RNA genes.
In our study, in Chinese hamster no complete genome is
available, UTRs are likely to be less-conserved and CHO
contains genes that are not present in mouse or rat.
Therefore, 60% of the reads which can be mapped
appears to be reasonable.
Nevertheless, these data also point to a larger number
of yet unknown genes and expressed elements in CHO for
which no close orthologs in mouse or rat exist.
As shown, 60% of the reads sequenced per sample are
still enough to perform a thorough gene expression
proﬁling of CHO, as demonstrated for the example of
butyrate treatment. We could identify many of the key
regulators involved in butyrate-mediated cell cycle arrest
in the G1 or G2 phase of the cell cycle and a consistent
down-regulation of many genes taking part in DNA rep-
lication prior to and during mitosis. Furthermore, several
other processes in the butyrate-treated cells seem to be
altered, starting from the composition of the extracellular
matrix and the secretion of growth factors to a change
in the level of proteins involved in ion transport,
ubiquitin-mediated protein degradation and cytokinesis.
In this analysis, NGS showed clear advantages over the
existing Aﬀymetrix chip platform for CHO. Throughout
all aﬀected pathways and biological functions, NGS
identiﬁed more diﬀerentially expressed genes. The
majority of those genes was contributed by 5000 addi-
tional genes which can be detected by NGS and which
are not spotted on the Aﬀymetrix chip. Additionally,
NGS may also overcome problems in probe design
and sensitivity in the absence of the complete genome.
Our analysis presented a yet unseen data quality that
sharpened our understanding of genes regulated by
butyrate and uncovered a number of processes and meta-
bolic pathways which could only be detected as
signiﬁcantly aﬀected by NGS.
Taken together, our results show that detailed proﬁling
of changes in gene expression is possible using NGS
even if the genome sequence of that organism is unavail-
able. This requires a more advanced bioinformatics
analysis pipeline compared to a standard expression
analysis. Data processing and analysis included
transcriptome assembly, contig annotation, as well as
the combination of information on related organisms
and assembled sequences during read mapping. We
showed that, once such a pipeline has been established,
NGS is a powerful new tool to step into the transcriptome
of genomically ‘unknown’ organisms for which expression
proﬁling is impossible or extremely time consuming
and expensive.
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